Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for people living with kidney disease. Please review our social media guidelines at: https://akebia.com/social-media-guidelines/

Pharmakon Advisors

AgeChem Venture Fund

Athenian Venture Partners

Satter Investment Management

Orchard Venture Partners

Triathlon Medical Venture Partners

Venture Investors

Novartis Venture Fund

Novo Holdings

Kearny Venture Partners

Akebia Therapeutics

Humanetics is a competitor of Akebia Therapeutics in the biopharmaceutical industry.

Humanetics

Unicycive Therapeutics competes with Akebia Therapeutics in the biopharmaceutical sector.

Unicycive Therapeutics

Viracta is a notable competitor of Akebia Therapeutics in the biopharmaceutical industry.

Viracta

Ultivue is a competitor of Akebia Therapeutics in the biotechnology and healthcare sectors.

Ultivue

Ohana Biosciences competes with Akebia Therapeutics in the biotechnology and pharmaceuticals sectors.

Ohana Biosciences

Matterworks is a competitor of Akebia Therapeutics in the biotechnology and pharmaceuticals sectors.

Matterworks

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. Akebia also offers Auryxia, a ferric citrate used to control serum phosphorus levels in adult patients with DD-CKD on dialysis and for the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	90374624
crunchbase profile	general	Nov 27, 2024 1:21 PM	1137ce77
li profile	general	Feb 7, 2024 10:10 PM	923918a9
translate crunchbase fundingrounds	general
peers	general	Feb 7, 2024 10:10 PM	b6aef231
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AKEBIA

Akebia Therapeutics, Inc.

Last Close

1.82

22/11 21:00

Market Cap

226.36M

Beta: -

Volume Today

1.99M

Avg: -